Uncategorized

Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy

Published

on

As Sangamo runs out of cash, Eli Lilly and Astellas have emerged as stalking horse bidders for key assets, including a Fabry gene therapy currently being submitted for potential FDA approval.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version